


2023-2024

American Heart Association

Funding from Programs and Other Non-Federal Sources

special event and program sponsorships and fees from approximately 15 percent of the AHA's \$1.3 billion total

cases, the funds will be received in future years. The chart provides details on funding from pharmaceutical and device manufacturers in proportion to all sources of revenue.



Following is a schedule of corporate funding provided to the American Heart Association from pharmaceutical and biotech companies and medical device manufacturers during fiscal year 2023-2024. The schedule reflects cash received during fiscal year 2023-2024 and revenue committed to the American Heart Association that will be received in future years.

2023- 2024 Corporate Funding Received from Pharmaceutical and Biotech Companies and Device Manufacturers		
Corporation	Total Cash Received During 2023- 2024 on Prior and Current Year Commitments (1)	2023- 2024 Commitments Receivable in the Future
Abbott	710,500	165,000
Alexion Pharmaceuticals Inc.	-	675,000
Alnylam Pharmaceuticals	150,000	150,000
Amgen, Inc.	3,100,000	812,500
Astellas Pharma Inc.	125,000	-
AstraZeneca		

NOTE: (1) Includes all cash received from corporate contributions greater than \$50,000. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2020- 2021 through fiscal year 2023 - 2024.